Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
December 10, 2023 2:00 PM 2 min read

Cigna Drops Humana Merger, Opts For $10 Billion Buyback Strategy

by Bibhu Pattnaik Benzinga Staff Senior Writer
Follow

In a recent development in the health insurance sector, Cigna Corporation (NYSE:CI) has withdrawn from its proposed merger with Humana Inc. (NYSE:HUM).

What Happened: The deal, poised to create a colossal entity in the industry with an estimated $140 billion, fell through due to disagreements over financial terms.

With the merger off the table, Cigna is redirecting its strategy towards smaller, targeted acquisitions, reports The Wall Street Journal.

These acquisitions, described as "bolt-on," signify a tactical pivot for the company. Initial discussions about Cigna acquiring Humana in a significant cash-and-stock transaction surfaced last month.

However, the proposal was met with skepticism from shareholders, leading to a notable decline in Cigna's stock value. Concerns centered on the proposed use of Cigna's stock in the transaction.

Rather than pursuing the acquisition, Cigna is planning a substantial stock buyback program. This initiative involves an additional $10 billion in stock repurchases, elevating the planned buybacks to $11.3 billion.

Also Read: This Is What Whales Are Betting On Cigna Group

Despite abandoning the merger, Cigna has maintained a positive outlook on the potential benefits of a partnership with Humana, especially in improving healthcare access and reducing consumer costs.

Despite the current administration's stringent approach to mergers and acquisitions, Cigna remains confident that a deal with Humana would have been viable from a regulatory standpoint.

The company intends to use a significant portion of its discretionary cash flow for share buybacks in the coming year, including repurchasing at least $5 billion of common stock by mid-2024.

As Cigna explores the sale of its Medicare Advantage business, the collapse of the Humana deal leaves it potentially on the sidelines of a vital and growing insurance market segment.

After its $54 billion acquisition of Express Scripts Holding, Cigna has emerged as a key player in pharmacy benefits and is expanding its Evernorth health services unit.

Related stocks such as UnitedHealth Group Inc. (NYSE:UNH) and Elevance Health Inc (NYSE:ELV), along with ETFs like the Health Care Select Sector SPDR Fund (NYSE:XLV) and the iShares U.S. Healthcare ETF (NYSE:IYH), often see movements in response to significant industry developments like this.

Now Read: Here's How Much You Would Have Made Owning Cigna Group Stock In The Last 10 Years

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
M&ANewsHealth CareTop StoriesGeneralAI Generated
CI Logo
CIThe Cigna Group
$281.27-1.22%
Overview
ELV Logo
ELVElevance Health Inc
$286.48-1.71%
HUM Logo
HUMHumana Inc
$180.73-0.01%
IYH Logo
IYHiShares U.S. Healthcare ETF
Not Available-%
UNH Logo
UNHUnitedHealth Group Inc
$288.65-0.04%
XLV Logo
XLVState Street Health Care Select Sector SPDR ETF
$153.90-0.01%
CI Logo
CIThe Cigna Group
$281.27-1.22%
Overview
ELV Logo
ELVElevance Health Inc
$286.48-1.71%
HUM Logo
HUMHumana Inc
$180.73-0.01%
IYH Logo
IYHiShares U.S. Healthcare ETF
Not Available-%
UNH Logo
UNHUnitedHealth Group Inc
$288.65-0.04%
XLV Logo
XLVState Street Health Care Select Sector SPDR ETF
$153.90-0.01%
Comments
Loading...